Adicet Bio (ACET)
(Real Time Quote from BATS)
$1.48 USD
+0.03 (2.07%)
Updated May 30, 2024 11:40 AM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Brokerage Reports
0 items in cart
Adicet Bio, Inc. [ACET]
Reports for Purchase
Showing records 21 - 40 ( 99 total )
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials; ADI-001 to Enter Registration-Directed Ph 2 in CAR-T r/r LBCL
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
Impressive Updated Phase 1 Data for ADI-001 in r/r NHL; DL4 Selected as RP2D; Pivotal Phase 2 Study Could Begin 1H24
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
ADI-001 Data Update: Focus Remains on Significant Post CAR-T Setting
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology- Takeaways from Day 3 of ASGCT 2023; Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
Positive Preclinical Data Announced For ADI-270
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
1Q23 Results; ADI-001 Updates Expected This Quarter, Pivotal Trial Could Start in 4Q23
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
ASGCT 2023 Abstract Roundup For Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
4Q22 Results; Plans for FDA Meeting in 2Q23 Regarding Potential Pivotal Study for ADI-001
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
Q4 Financials; ADI-001 Development to Mature in 2023
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
HCW 2023 Top Picks: Seize the Opportunities
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
Positive Updated ADI-001 Data at ASH; Pivotal Study Could Begin in 2Q23; Raise PT by $4
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
ADI-001 Ph 1 Data Update; Post-CAR-T Setting Near Term Opportunity
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
SITC 2022 Conference Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: Research Department